Veeva Systems Inc. — FY2024 Form 10-K
Reporting period: Fiscal year ended January 31, 2024, compared primarily with FY2023. This is an annual filing, not a standalone 2023 fourth-quarter report.
Business context
Veeva provides cloud software, data, analytics, professional services, and consulting, primarily to the life sciences industry. It reports one operating segment. At year-end it served 1,432 customers, up from 1,388. Commercial Solutions include commercial software and data products; R&D Solutions support clinical, regulatory, quality, and safety functions.
Financial performance
| Metric | FY2024 | FY2023 | Change |
|---|---|---|---|
| Total revenue | $2.364 billion | $2.155 billion | +10% |
| Subscription services revenue | $1.902 billion | $1.733 billion | +10% |
| Professional services and other revenue | $462 million | $422 million | +9% |
| Gross profit / gross margin | $1.686 billion / 71% | $1.546 billion / 72% | +9% / down 1 point |
| Operating income | $429 million | $459 million | Down 6% |
| Net income | $526 million | $488 million | +8% |
| Diluted earnings per share | $3.22 | $3.00 | +7% |
| Operating cash flow | $911 million | $780 million | +$131 million |
- R&D Solutions subscription revenue grew by $119 million; Commercial Solutions subscription revenue grew by $50 million. R&D represented 50% of total revenue, versus 48% in FY2023.
- Operating expenses rose 16% to $1.257 billion, led by R&D expense growth of 21% to $629 million. R&D spending was 27% of revenue, compared with 24%.
- Other income, net, rose to $159 million from $50 million, primarily because interest income increased by $88 million. The effective tax rate increased to 10.6% from 4.2%.
- Stock-based compensation was $394 million, up from $352 million.
Liquidity, cash flow, and debt
- Cash, cash equivalents, and short-term investments totaled approximately $4.0 billion at January 31, 2024, including $703 million of cash and cash equivalents and $3.324 billion of short-term investments.
- Current assets were $5.003 billion and current liabilities were $1.179 billion. Deferred revenue was $1.050 billion.
- Cash from operations was $911 million; investing activities used $1.076 billion, primarily reflecting net purchases of investments; financing activities used $16 million.
- The filing reports no conventional borrowings in the presented balance sheet. Lease liabilities totaled $55.8 million, including current and noncurrent amounts.
- Management stated existing cash, investments, and operating cash flows should meet working capital and capital expenditure needs for at least the next 12 months.
Changes, outlook, and management commentary
- Revenue growth slowed to 10% from 16% in FY2023. Management attributed FY2024 growth pressure to macroeconomic conditions, reduced funding in parts of the customer base, increased scrutiny of potential projects, foreign exchange, and a change to customer contract terms.
- Since February 2023, master subscription agreements for multi-year orders generally include customer termination-for-convenience rights. The change affected revenue recognition and reduced FY2024 revenue and unbilled revenue. Beginning in FY2025, revenue on these orders is generally expected to align with invoicing for the relevant term.
- Management expects revenue growth to accelerate in FY2025 compared with FY2024, partly because FY2024 revenue was reduced by the contract change. It also expects operating expenses to rise, primarily from employee compensation; subscription service costs are expected to increase with usage and data costs.
- Management expects FY2025 cash flow from operations to be reduced by income tax payments related to required capitalization and amortization of R&D costs under the Tax Cuts and Jobs Act; the impact in later periods is not quantified.
- Vault CRM was in use by early adopters, with general availability planned for April 2024. Veeva CRM is to be supported through September 1, 2030. The company plans to migrate CRM customers from Salesforce-based applications to its Vault platform and does not intend to renew its Salesforce agreement when its term ends September 1, 2025.
Risks, contingencies, and unusual items
- Key risks include successful adoption and migration to Vault CRM, competition from IQVIA and Salesforce, reliance on third-party infrastructure and data providers, customer concentration, cybersecurity and privacy exposure, and macroeconomic and life-sciences industry conditions.
- Veeva and IQVIA are engaged in multiple disputes involving alleged trade-secret misappropriation, antitrust, and data access. A trial date of February 10, 2025 was set for the IQVIA litigation matters; Veeva stated it could not meaningfully estimate potential gain or loss. Veeva’s counterclaims seek injunctive relief and damages exceeding $200 million.
- A separate Mednet lawsuit remains in discovery; Veeva also stated it could not meaningfully estimate potential loss. The Medidata case was resolved in Veeva’s favor, and the appeal was dismissed in January 2024.
- Foreign-exchange movements negatively affected reported revenue. A 100-basis-point immediate interest-rate increase was estimated to reduce the investment portfolio’s market value by $43 million; a decrease of the same size was estimated to increase it by $43 million.
- The filing identifies no goodwill impairment or material accrued liability for customer indemnification obligations. KPMG gave unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective.
Important facts for investors to verify
- Whether FY2025 revenue growth accelerates as management expects, and how much of the comparison reflects the FY2024 contract-accounting change.
- Vault CRM availability, customer migration pace, retention, performance, and the financial and operational costs of the transition.
- Whether R&D Solutions growth can offset slower Commercial Solutions growth and the impact of customer spending scrutiny.
- Developments and potential financial exposure in the IQVIA and Mednet litigation, including the scheduled IQVIA trial.
- The effect of rising operating costs, substantial stock-based compensation, tax payments, and investment yields on operating profitability and cash generation.